The anthracycline antineoplastic drugs.
D015250:Aclarubicin; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002360:Carubicin / Q000627:therapeutic use; D003630:Daunorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006027:Glycosides / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D009279:Naphthacenes / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D006027:Glycosides; D009279:Naphthacenes; C016163:valrubicin; D015250:Aclarubicin; D004317:Doxorubicin; D002360:Carubicin; C002205:zorubicin; D003630:Daunorubicin